Shares in Mayne Pharma Group Ltd (ASX: MYX) have climbed around 8% at the time of writing following the release of the company's third-quarter update.
The move extends a sharp rebound that has seen Mayne Pharma's share price rise 32% since hitting a five-year low in March this year.
That share price rebound has put the company back on investors' radar and raises a key question: Is this just a dead cat bounce, or the start of something more durable?
Image source: Getty Images
Momentum is starting to build
The latest update points to early signs of improving momentum across the business.
A major highlight was the launch of DistributeRx, Mayne Pharma's new prescription distribution platform. Early results have been encouraging, with prescription volumes significantly exceeding internal expectations and continuing to build as new prescribers come on board.
This is strategically important. DistributeRx represents a shift in how the company engages with the market, with the company moving beyond individual products to a broader ecosystem approach. If it scales as planned, it could become a meaningful growth driver.
At the same time, the company's women's health portfolio continues to perform well.
Prescriptions for BIJUVA® rose strongly, while demand for NEXTSTELLIS® also increased. These products sit in attractive, growing markets and are central to Mayne Pharma's strategy of focusing on higher-value segments.
Financials still catching up
While operational momentum is improving, the financials are still in transition.
Revenue growth (+1%) was broadly flat for the quarter, but gross margins improved, reflecting better pricing discipline and product mix. Underlying EBITDA also moved closer to breakeven, although the business remains loss-making.
One area that stood out was cash flow.
The company generated strong operating cash flow during the quarter, boosting its cash position and providing greater flexibility to reinvest in growth initiatives. That's an important foundation, particularly for a business still working towards consistent profitability.
Is this the bottom?
Mayne Pharma shares had been under significant pressure, falling to around $2.20 in March 2026, their lowest level in five years. The recent 32% rally from that low point suggests sentiment may be starting to shift.
But it's too early to call a full turnaround.
For that to happen, investors will want to see continued execution (particularly with sustained sales growth of DistributeRx) alongside sustained growth in key product segments and a clearer path to profitability.
Foolish bottom line
Mayne Pharma's latest update suggests the business is moving in the right direction, and the share price is starting to respond. But after a long period of underperformance, investors will be looking for consistent delivery before concluding that the bottom is truly in.
